2024-04-10 07:17:31 ET
DENVER, Colo., Apr 10, 2024 ( 247marketnews.com )- IN8bio, Inc. (NASDAQ: INAB ) reported, after yesterday’s market close, new preclinical data from INB-300, its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell platform, which demonstrated improved selectivity to target leukemia cells while preserving healthy ones.
The data potentially supports nsCAR for a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target and was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.
“INB-300 can selectively target leukemia cells while preserving healthy tissue. We are now conducting further optimization to improve the integration of membrane-bound IL-15 co-expression to potentially enhance both the efficacy and safety of next-generation adoptive cell therapies against a wider spectrum of cancers,” said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. “These results can potentially improve INB-300, as we advance towards IND enabling studies of our next-generation gamma-delta T cell therapies to treat cancers.”
The post IN8bio Presents New Preclinical Data at AACR 2024 appeared first on 24/7 MarketNews .
For further details see:
IN8bio Presents New Preclinical Data at AACR 2024